A low dose treatment of interleukin-2 (IL-2), an immune signaling protein, improved salivary gland function in a Sjögren’s syndrome mouse model, but it didn’t reverse immune-mediated structural damage to the glands, a study showed. Although IL-2 may improve salivary gland function in Sjögren’s, combining it with other immunomodulatory therapies…
News
Motto Health has launched a type of virtual clinic — with rheumatologists and healthcare professionals — for people with autoimmune and chronic inflammatory conditions, including Sjögren’s syndrome, the startup announced. Through an online application, the platform allows patients to schedule virtual appointments with specialists, manage and track symptoms,…
People with a history of herpes zoster infection, mainly those with no other health conditions, are at an increased risk of developing Sjögren’s syndrome, according to a nationwide, population-based study in Taiwan. Its researchers emphasized the importance of screening for Sjögren’s in patients with herpes zoster infection, particularly among…
Age, disease duration, and blood levels of inflammatory markers Krebs von den Lungen-6 (KL-6) and TNF-alpha are the most discriminating factors for identifying Sjögren’s syndrome patients with interstitial lung disease, a study found. While less significantly associated, other inflammatory markers, including immunoglobulin M (IgM), c-reactive protein (CRP), eotaxin, and…
Sugar metabolism — all chemical reactions involved in making or breaking down glucose, or blood sugar — is overly active in B-cells, a type of immune cell implicated in Sjögren’s syndrome, and may provide a target for developing treatments, a study suggests. The study, “mTORC1-GLUT1-mediated glucose metabolism drives…
People with Sjögren’s syndrome are more likely to require inpatient hospital care for infections acquired in the community, especially those of the airways and intestines, according to a large nationwide French study. “[Sjögren’s] patients had a significantly higher incidence rate of hospitalization for bronchopulmonary infections compared with matched [healthy…
Cytotoxic CD8+ T-cells, a type of immune cells, build up in the salivary glands of the lips of patients with severe Sjögren’s syndrome, where they may kill the epithelial cells that line the glands, according to a new study. As these cells die, the glands no longer can produce…
A protein called ETS1 is present in large amounts in cells in the salivary glands of patients with Sjögren’s syndrome, where it may turn on a switch to make more of MMP-9, another protein that has been implicated in the early development of the disease, a study found. Researchers…
The investigational therapy dazodalibep markedly eased disease activity in people with Sjögren’s syndrome with moderate-to-high systemic disease activity, meeting the primary goal of a Phase 2 trial. Ahead of expectations, the therapy’s developer, Horizon Therapeutics, plans to work with the U.S. Food and Drug Administration (FDA) to design…
A non-invasive imaging technique called in vivo confocal microscopy, or IVCM for short, was found to detect changes in the density and structure of nerve fibers in the cornea of the eyes in adults with Sjögren’s syndrome. IVCM’s ability to detect such changes in the corneal nerves support its…
Recent Posts
- Efgartigimod shows signals of benefit in Sjögren’s disease clinical trial
- Sjögren’s symptoms differ by sex, but overall impact similar
- Sjögren’s symptoms extend far beyond dryness, U.S. survey finds
- Study links anti-Ro antibody patterns to disease features in Sjögren’s
- Global trial of telitacicept for Sjögren’s doses first patient ‘within weeks’
- Patients, advocates working this month to raise awareness of Sjögren’s
- Biotech, US university partner on new ways to speed Sjögren’s diagnosis
- New study links alternative splicing patterns to Sjögren’s severity
- Initial data from trial testing CLN-978 in Sjögren’s expected this year
- Sjögren’s disease may increase risk of certain digestive cancers: Korean study